ASH 2018 Annual Meeting Highlights in MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 28, 2018
Expiration Date: December 28, 2019

Expected time to complete this activity as designed: 60 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, participants will hear key highlights taken from of a select group of abstracts which focused on some of the most impactful data in myelodysplastic syndromes (MDS), presented at the 2018 American Society of Hematology (ASH) 60th Annual Meeting. Leading experts in the field of MDS will share their insights on a variety of abstracts, covering topics including, but not limited to: efficacy and safety of novel agents such as pracinostat, ivosidenib and selinexor, and immune checkpoint inhibitors such as nivolumab and ipilimumab, an update on the Medalist Trial, rigosertib combined with azacitidine in patients with higher-risk MDS, and a look at the Connect® MDS/AML Disease Registry.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize the efficacy and safety data from clinical trials investigating novel therapies and treatment strategies in patients with myelodysplastic syndromes (MDS)
  • Describe expert faculty perspectives on key clinical trial data for novel therapies and treatments strategies in MDS
  • Recognize the potential impact of clinical trials on clinical practice and existing treatment paradigms in MDS

Agenda

Combination of Pracinostat and Azacitidine in Patients with High/Very High-Risk MDS – Ehab Atallah, MD

Nivolumab or Ipilimumab with or without Azacitidine for Patients with MDS – Guillermo Garcia-Manero, MD

Double Immune Checkpoint Inhibition in Patients with MDS – Guillermo Garcia-Manero, MD

Safety and Efficacy of Deferasirox Vs. Placebo in Iron-Overloaded Patients with Low- and Intermediate-1-Risk MDS – Guillermo Garcia-Manero, MD

Initial Results of a Phase 1/2 Study of Tomaralimab for Patients with Low-risk MDS – Guillermo Garcia-Manero, MD

Oral Rigosertib Combined with Azacitidine in Patients with Higher-Risk MDS – Shyamala C. Navada, MD, MSCR

The MEDALIST Trial of Luspatercept in Patients with Very Low-, Low-, or Intermediate-Risk MDS – David P. Steensma, MD, FACP

Factors Associated with Early Therapy Initiation in Patients with MDS – David P. Steensma, MD, FACP

Update on the Imetelstat Clinical Trial in MDS – David P. Steensma, MD, FACP

Ivosidenib Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant R/R MDS – Eytan M. Stein, MD

Selinexor Is Efficacious and Tolerable in Patients with MDS Refractory to HMAs – Eytan M. Stein, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 28, 2019. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Ehab Atallah, MD
Associate Professor of Medicine
Section Head, Hematologic Malignancies/BMT
Division of Hematology & Oncology
Medical College of Wisconsin
Milwaukee, Wisconsin

Dr. Ehab Atallah received his medical degree from Cairo University School of Medicine. He completed an internal medicine residency in the Cleveland Clinic Health System, a fellowship in hematology/oncology at the Karmanos Cancer Center, where he served as chief fellow, as well as a leukemia fellowship at MD Anderson Cancer Center. Dr. Atallah is Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology, specializing in leukemia and myelodysplastic syndromes at Froedtert Hospital.

Dr. Atallah is board certified in internal medicine, medical oncology, and hematology. He has authored numerous publications, including journal articles and meeting abstracts. His current research interests include the treatment of patients with chronic myelogenous leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myelogenous leukemia, myeloproliferative neoplasms, and myelodysplastic syndromes.

Guillermo Garcia-Manero, MD
Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dr. Guillermo Garcia-Manero received his medical degree from the University of Zaragoza, Spain. He completed his clinical internship, residency, and clinical fellowship in hematology and medical oncology at Thomas Jefferson University Hospital, Philadelphia. Dr. Garcia-Manero is Professor and Chief, Section of Myelodysplastic Syndromes (MDS) and Deputy Chair of Translational Research, Department of Leukemia, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center (UTMDACC) in Houston. In addition, he is Co-Director, DNA Methylation Core, and the endowed Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research, Department of Leukemia, Division of Cancer Medicine, at UTMDACC.

Dr. Garcia-Manero is board certified in medical oncology (hematology eligible), and internal medicine. He holds membership in the American Association for the Advancement of Science, American Society of Hematology, American Society of Clinical Oncology, American Association of Cancer Research (Chair, Scientific Review Committee), Aplastic Anemia and International Myelodysplastic Syndromes Foundation (Steering Committee/Medical Advisory Board), American Medical Association (AMA) Foundation, Society of Hematologic Oncology, and the European Hematology Association. In addition, he is an editor/journal reviewer for numerous peer-reviewed publications. Dr. Garcia-Manero has written more than 800 abstracts, invited articles, and editorials in scientific journals, and is the Principal Investigator in several MDS studies.

Shyamala C. Navada, MD, MSCR
Assistant Professor
Mount Sinai School of Medicine
Department of Medicine
Division of Hematology/Oncology
New York, New York

Dr. Shyamala Navada received her medical degree from the University of Illinois College of Medicine in Chicago, as well as a master’s of science in clinical research from Mount Sinai School of Medicine. She completed a medical residency at the University of Michigan Hospitals and a hematology/oncology fellowship at Mount Sinai School of Medicine in New York City. Dr. Navada is Assistant Professor at Mount Sinai School of Medicine, Department of Medicine, Division of Hematology/Oncology, where she is also an Assistant Attending Physician.

Dr. Navada is board certified in internal medicine, hematology, and medical oncology. Her research focus is on designing early phase trials that investigate the role of novel drugs to improve the outcome of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). She has been involved in numerous clinical trials for these patients, and has presented at national and international meetings, including the American Society of Hematology annual meeting, International Bone Marrow Failure Disease Scientific Symposium, International Symposium on Myelodysplastic Syndromes, and European Hematology Association Congress. Dr. Navada is the author/co-author of medical textbook chapters and articles in peer-reviewed journals, including The Journal of Clinical Investigation and Leukemia Research. As a clinical expert and recognized leader in the medical management of MDS and AML, she also educates community physicians on the treatment of MDS through the Aplastic Anemia and MDS Foundation.

David P. Steensma, MD, FACP
Associate Professor of Medicine
Harvard Medical School
Institute Physician
Dana-Farber Cancer Institute
Boston, Massachusetts

Dr. David Steensma received his medical degree from the University of Chicago’s Pritzker School of Medicine. He completed an internal medicine residency and a combined hematology-oncology fellowship at the Mayo Clinic in Rochester, Minnesota. He is Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Hematological Malignancies at Dana-Farber Cancer Institute in Boston, Massachusetts, where he co-directs the hematological malignancy precursor clinic. In addition, Dr. Steensma is a consulting physician at Brigham & Women’s Hospital.

Following completion of his formal training, Dr. Steensma spent several years as a visiting research scholar in the Molecular Haematology Unit of the Weatherall Institute of Molecular Medicine, University of Oxford, England, investigating the molecular genetics of myelodysplastic syndromes. He is board certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. Dr. Steensma has published more than 300 peer-reviewed papers, served as editor for several American Society of Hematology (ASH) publications, education co-chair for the ASH Annual Meeting, section editor for the Journal of Clinical Oncology, member of the FDA Oncology Drug Advisory Committee, and on the hematology examination committee of the American Board of Internal Medicine.

Eytan M. Stein, MD
Assistant Professor
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Eytan Stein received his medical degree from Northwestern University in Chicago, where he also completed his internal medicine residency. He then completed his fellowships in medicine at Weill Cornell Medical College, and in medical oncology and hematology at Memorial Sloan Kettering. He is an Assistant Professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center in New York City.

Dr. Stein holds board certification from the American Board of Internal Medicine, American Board of Clinical Oncology, and the American Board of Hematology. He focuses his practice on the treatment of acute and chronic leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms. His research interests include developing novel, early phase clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-18-056-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 18-056-094

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Ehab Atallah has received honoraria as a consultant from Agios, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., and Takeda Oncology.

Dr. Guillermo Garcia-Manero has disclosed no relevant financial relationships.

Dr. Shyamala Navada has received grant support related to research activities from Astellas Pharma US, Inc. and Onconova Therapeutics.

Dr. David Steensma has received honoraria as a consultant from Novartis AG, Otsuka Pharmaceutical Co., Ltd., and Sensei Biotherapeutics as well as formal advisory activities from Onconova Therapeutics, PharmaEssentia Corporation, and Takeda Oncology.

Dr. Eytan Stein has received honoraria related to formal advisory activities from Agios, Astellas Pharma US, Inc., Bayer AG, Celgene Corporation, Daiichi Sankyo, Inc., Novartis AG, and Pfizer Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Kristin Burke, Project Manager, Joan Meyer, RN, MHA, Executive Director, and Bill Stoff, Director of Operations, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Onconova Therapeutics Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.